Early DHA Supplementation in Very Low Birth Weight Infants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
Evanston, Illinois, United States, 60201
- North Shore University Health System
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Very low birth weight infants weighing less than 1500 grams
- Consent signed within 72 hours of life
Exclusion Criteria:
- Infants with know metabolic disorder
- Infants with known congenital GI anomaly
- Infants who are deemed to be inappropriate for enrollment per attending neonatologist
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Placebo
|
|
Experimental: Low dose PUFA
|
Low dose PUFA
|
|
Experimental: High dose PUFA
|
High dose PUFA
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Red Blood Cell polyunsaturated fatty acids (PUFA) levels
Time Frame: 2 weeks of age
|
2 weeks of age
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Red Blood Cell PUFA levels
Time Frame: 8 weeks of age
|
8 weeks of age
|
|
|
Feeding tolerance
Time Frame: 8 weeks
|
Full enteral feed of 120 kcal/kg/day
|
8 weeks
|
|
Incidence of necrotizing enterocolitis
Time Frame: 8 weeks
|
8 weeks
|
|
|
Incidence of bronchopulmonary dysplasia
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Timothy Cooper, M.D, Mead Johnson Nutrition
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 6039
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prematurity
-
NCT07198360Not yet recruitingIntraventricular Hemorrhage of Prematurity
-
NCT07157020Not yet recruitingIntraventricular Hemorrhage of Prematurity
-
NCT02147769CompletedIntraventricular Hemorrhage of Prematurity | Complications of Prematurity
-
NCT01498133Unknown
-
NCT02632266Completed
-
NCT01305720Unknown
-
NCT00238056CompletedPrematurity and Feeding Intolerance
-
NCT00917085CompletedModerate to Late Prematurity
Clinical Trials on Placebo
-
NCT03827590UnknownAcute Bronchitis | Acute Upper Respiratory Tract Infection
-
NCT02177513Completed
-
NCT06767540Not yet recruiting
-
NCT02935712CompletedMale Subjects With Type II Diabetes (T2DM)
-
NCT03198624CompletedPharmacokinetics | Safety Issues
-
NCT02982187CompletedPulmonary Disease, Chronic Obstructive
-
NCT04388215UnknownHypertension | Dyslipidemias
-
NCT04693039Completed
-
NCT01610388Completed